- Home
- MRK vs MA Comparison
MRK vs MA Comparison
Compare MRK & MA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRK | MA |
|---|---|---|
| Founded | 2000 | 1966 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.2B | 431.9B |
| IPO Year | 1994 | 2005 |
Fundamental Metrics
Financial Performance| Metric | MRK | MA |
|---|---|---|
| Price | $121.37 | $497.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 26 |
| Target Price | $125.59 | ★ $649.19 |
| AVG Volume (30 Days) | ★ 8.6M | 3.6M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.06% | 0.66% |
| EPS Growth | 8.01 | ★ 18.93 |
| EPS | N/A | ★ 4.35 |
| Revenue | ★ $65,011,000,000.00 | $32,791,000,000.00 |
| Revenue This Year | $3.61 | $16.19 |
| Revenue Next Year | $5.41 | $12.35 |
| P/E Ratio | ★ N/A | $112.21 |
| Revenue Growth | 1.31 | ★ 16.42 |
| 52 Week Low | $76.66 | $464.52 |
| 52 Week High | $125.14 | $601.77 |
Technical Indicators
Market Signals| Indicator | MRK | MA |
|---|---|---|
| Relative Strength Index (RSI) | 60.28 | 52.81 |
| Support Level | $112.96 | $487.11 |
| Resistance Level | $123.93 | $529.49 |
| Average True Range (ATR) | 2.97 | 9.83 |
| MACD | 0.05 | 0.88 |
| Stochastic Oscillator | 83.56 | 70.59 |
Price Performance
Historical ComparisonAbout MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
About MA Mastercard Incorporated
Mastercard is the second-largest payment processor in the world, having processed close to $11 trillion in volume during 2025. Mastercard operates in over 200 countries and processes transactions in over 150 currencies.